Alopecia

• 

  Subject Areas on Research

  • A falling out following minoxidil: telogen effluvium. 
  • A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. 
  • A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. 
  • A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. 
  • A spontaneous deletion within the desmoglein 3 extracellular domain of mice results in hypomorphic protein expression, immunodeficiency, and a wasting disease phenotype. 
  • Adriamycin in the treatment of childhood acute leukemia. A Southwest Oncology Group study. 
  • Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study. 
  • Alopecia associated with fluconazole therapy. 
  • Alopecia in IL-10-deficient mouse pups is c-kit-dependent and can be triggered by iron deficiency. 
  • Alopecia: evaluation and management. 
  • Authors' reply. 
  • Basal cell carcinoma originating from a nevus sebaceus on the scalp of a 7-year-old boy. 
  • Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. 
  • Central centrifugal cicatricial alopecia. 
  • Central hair loss in African American women: incidence and potential risk factors. 
  • Central scalp alopecia photographic scale in African American women. 
  • Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. 
  • Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. 
  • Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. 
  • Correspondence re: E. Hawk, et al., Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol.Biomark. Prev., 9: 523-527, 2000. 
  • Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. 
  • Cyclic Alopecia and Abnormal Epidermal Cornification in Zdhhc13-Deficient Mice Reveal the Importance of Palmitoylation in Hair and Skin Differentiation. 
  • Dose-response study of topical minoxidil in male pattern baldness. 
  • Dosimetric analysis of the alopecia preventing effect of hippocampus sparing whole brain radiation therapy. 
  • Early onset baldness and prostate cancer risk. 
  • Ectodermal dysplasia: otolaryngologic manifestations and management. 
  • Effect of ultraviolet light on topical minoxidil-induced hair growth in advanced male pattern baldness. 
  • Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study. 
  • Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. 
  • Efficacy of finasteride 1 mg in the treatment of androgenetic alopecia in men. 
  • Evaluation and treatment of male and female pattern hair loss. 
  • Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. 
  • Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. 
  • Female pattern hair loss. 
  • Female pattern hair loss. 
  • Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. 
  • Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. 
  • Focal atrichia: A diagnostic clue in female pattern hair loss. 
  • Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. 
  • Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. 
  • Guidelines of care for androgenetic alopecia. American Academy of Dermatology. 
  • Hair loss among elderly men: etiology and impact on perceived age. 
  • Human FOXN1-deficiency is associated with αβ double-negative and FoxP3+ T-cell expansions that are distinctly modulated upon thymic transplantation. 
  • Human equivalent of the mouse Nude/SCID phenotype: long-term evaluation of immunologic reconstitution after bone marrow transplantation. 
  • Iron deficiency and hair loss: the jury is still out. 
  • Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. 
  • Keratosis follicularis spinulosa decalvans in a family. 
  • Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. 
  • Long-term follow-up of men with male pattern baldness treated with topical minoxidil. 
  • Mice with alopecia, osteoporosis, and systemic amyloidosis due to mutation in Zdhhc13, a gene coding for palmitoyl acyltransferase. 
  • Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis. 
  • My hair is thinning on the top of my head. What treatments are available for hair loss in women? 
  • Occupational alopecia or alopecia areata? 
  • Persistent Rash in a Patient Receiving Total Parenteral Nutrition. 
  • Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial. 
  • Phase II study of docetaxel in advanced soft tissue sarcomas. 
  • Pityriasis amiantacea: a report of two cases in adults. 
  • Quality of life of cutaneous disease in the ectodermal dysplasias. 
  • Resource utilization and quality of life associated with congenital ichthyoses. 
  • SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. 
  • Scalp comedones after topical minoxidil. 
  • Serum androgens: associations with prostate cancer risk and hair patterning. 
  • Serum androgens: associations with prostate cancer risk and hair patterning. 
  • Skin manifestations in individuals of African or Asian descent. 
  • Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001. 
  • The Danish Twin Registry in the new millennium. 
  • The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. 
  • The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women. 
  • The near-naked hairless (Hr(N)) mutation disrupts hair formation but is not due to a mutation in the Hairless coding region. 
  • Tinea capitis mimicking dissecting cellulitis. 
  • Topical minoxidil in early male pattern baldness. 
  • Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. 
  • Transdermal viprostol in the treatment of male pattern baldness. 
  • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. 
  • Treatment of chemotherapy-induced alopecia. 
  • Update on cicatricial alopecia. 
• 

  Keywords of People

  • Liu, Yutao, Adjunct Assistant Professor in the Department of Medicine, Medicine, Medical Genetics
  • Olsen, Elise Arline, Professor of Dermatology, Dermatology